While this platform will first be set up and developed for novel drugs in hematologic malignancies, future perspectives include a broader translational approach both with regard for diseases (e.g. solid tumors) and synthetic derivatives.
Based on the promising data of chalcones in cell lines and patient cells, we plan to conduct studies in mouse models to assess cytotoxicity in vivo and to characterize the pathways involved in the induction of cell death by these compounds. Thus, we want to gain knowledge on the molecules involved in drug-cell interactions and the behavior of the drugs in organisms. These experiments not only will provide information for the potential development of future drugs but also pave the way for bringing the compounds to the clinics by helping in initiating clinical trials.